The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1696
February 19, 2024
View Complete Issue         Table of Contents 2019 
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
February 19, 2024 (Issue: 1696)
The FDA has approved daprodustat (Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
Article code: 1696a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.